Oncology Medical News about Neoplasms Pain Administration, Sublingual Fentanyl

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain
Current Medical Research and Opinion, 10/13/09

Rauck RL et al. – Sublingual fentanyl ODT was efficacious and well–tolerated for the treatment of BTcP in opioid–tolerant patients with cancer. Sublingual fentanyl ODT provided significant improvements in pain intensity compared to placebo, from 10min post–administration and throughout the 60–min post–dose assessment period. Sublingual fentanyl ODT was well tolerated over 12months of treatment.

<< Previous
Surgery of low-grade gliomas: towards a functional neurooncology

Next >>
Bortezomib: a new therapeutic option for POEMS syndrome